Bresch argued that the problem of drug prices isn't with Mylan or even the pharmaceutical industry, but instead with a health-care system that often requires consumers to pay not just insurance premiums also out-of-pocket for prescription medications, sometimes to the full retail price.

That phenomenon, Mylan has said, has been exacerbated by the increase in the number of high-deductible health plans.